Skip to content
10-Q

Quarterly Report

PMV PHARMACEUTICALS, INC. PMVP

0000950170-24-122817

← back to feed
Filed
Nov 7, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2024 · Nov 6, 2024 51.75M sh
Cash And Equivalents Q3 2024 · Sep 30, 2024 $48.81M
Cash And Equivalents Q3 2024 · Dec 31, 2023 $37.71M
Current Liabilities Q3 2024 · Sep 30, 2024 $13.56M
Current Liabilities Q3 2024 · Dec 31, 2023 $14.03M
Total Liabilities Q3 2024 · Sep 30, 2024 $25.59M
Total Liabilities Q3 2024 · Dec 31, 2023 $26.46M
Current Assets Q3 2024 · Sep 30, 2024 $189.62M
Current Assets Q3 2024 · Dec 31, 2023 $207.41M
Total Assets Q3 2024 · Sep 30, 2024 $223.5M
Total Assets Q3 2024 · Dec 31, 2023 $252.15M
Shares Diluted Q3 2024 · Sep 30, 2023 49.05M sh
Shares Diluted Q3 2024 · Sep 30, 2023 46.89M sh
Capex Q3 2024 · Sep 30, 2023 $765K
Operating Cash Flow Q3 2024 · Sep 30, 2023 −$43.57M
Stockholders Equity Q3 2024 · Sep 30, 2023 $237.61M
Stockholders Equity Q3 2024 · Jun 30, 2023 $217.81M
Stockholders Equity Q3 2024 · Mar 31, 2023 $230.17M
Stockholders Equity Q3 2024 · Dec 31, 2022 $246.03M
Eps Diluted Q3 2024 · Sep 30, 2023 −$0.34
Eps Diluted Q3 2024 · Sep 30, 2023 −$1.13
Eps Basic Q3 2024 · Sep 30, 2023 −$0.34
Eps Basic Q3 2024 · Sep 30, 2023 −$1.13
Sga Expense Q3 2024 · Sep 30, 2023 $6.04M
Sga Expense Q3 2024 · Sep 30, 2023 $18.73M
Rd Expense Q3 2024 · Sep 30, 2023 $13.59M
Rd Expense Q3 2024 · Sep 30, 2023 $42.5M
Net Income Q3 2024 · Sep 30, 2023 −$16.64M
Net Income Q3 2024 · Sep 30, 2023 −$53.2M
Net Income Q3 2024 · Jun 30, 2023 −$17.44M
Net Income Q3 2024 · Mar 31, 2023 −$19.13M
Operating Income Q3 2024 · Sep 30, 2023 −$19.63M
Operating Income Q3 2024 · Sep 30, 2023 −$61.23M